摘要
背景:多发性骨髓瘤(MM)是以骨髓内浆细胞的增殖为特征的克隆性B细胞恶性肿瘤,仍是一种无法治愈的疾病,因此,迫切需要寻找新的治疗靶点。虽然microRNA-137 (miR-137)(参与多种细胞过程)已被报道在许多类型的肿瘤中低水平表达,其在MM中的作用仍不知道。 方法:在这项研究中,研究了在MM的miR-137靶基因和潜在的影响。 结果:结果显示MM患者的MM细胞株和CD138 +骨髓单个核细胞中miR-137表达明显下调的。双荧光素酶报告基因分析显示,MITF是miR-137直接目标。miR-137的超表达或MITF-shRNA的转染对丝氨酸/苏氨酸蛋白激酶(Akt)表达无显著影响,但MITF、c-Met、p-Akt蛋白的表达及其磷酸化底物蛋白明显下降,同时伴随着p53表达增加。此外,miR-137或MITF-shRNA的超表达显著提高了用地塞米松处理过的多发性骨髓瘤细胞36小时抑制率和凋亡率。MITF表达增加可能抵消在多发性骨髓瘤细胞中miR-137的生物学效应。 结论:我们的结论是MITF是miR-137的直接目标。miR-137可以通过降低受体的表达,进一步以MITF为目标降低Akt磷酸化提高多发性骨髓瘤细胞的激素敏感性。
关键词: AKT,c-Met,地塞米松敏感,miR-137,MITF,多发性骨髓瘤,磷酸化
图形摘要
Current Cancer Drug Targets
Title:miR-137 Suppresses the Phosphorylation of AKT and Improves the Dexamethasone Sensitivity in Multiple Myeloma Cells Via Targeting MITF
Volume: 16 Issue: 9
Author(s): Benping Zhang, Ling Ma, Jia Wei, Jingyu Hu, Zichu Zhao, Youping Wang, Yan Chen, Fei Zhao
Affiliation:
关键词: AKT,c-Met,地塞米松敏感,miR-137,MITF,多发性骨髓瘤,磷酸化
摘要: Background: Multiple myeloma (MM), a clonal B cell malignancy characterized by the proliferation of plasma cells within the bone marrow, is still an incurable disease, and therefore, finding new therapeutic targets is urgently required. Although microRNA-137 (miR-137), which is involved in a variety of cellular processes, has been reported to be under-expressed in many types of solid tumors, its role in MM is less known.
Methods: In this study, the target gene and the potential effect of miR-137 in MM were investigated.
Results: The results showed significantly down regulated expression of miR-137 in MM cell lines and in the CD138+ bone marrow mononuclear cells of MM patients. A dual luciferase reporter gene analysis revealed that MITF is a direct target of miR-137. The overexpression of miR-137 or transfection of MITF-shRNA had no significant effect on the expression of serine/ threonine protein kinase (AKT), but the expression of MITF, c-MET, p-AKT, and its phosphorylated substrate protein decreased significantly, which was accompanied by an increase in p53 expression. In addition, the overexpression of miR-137 or MITF-shRNA significantly improved the 36-hour inhibition rate and apoptosis rate in multiple myeloma cells treated with dexamethasone. The overexpression of MITF could counteract the biological effect of miR-137 in multiple myeloma cells.
Conclusion: We conclude that MITF is a direct target of miR-137. The miR-137 can improve the dexamethasone sensitivity in multiple myeloma cells by reducing the c-MET expression and further decreasing the AKT phosphorylation via targeting MITF.
Export Options
About this article
Cite this article as:
Benping Zhang, Ling Ma, Jia Wei, Jingyu Hu, Zichu Zhao, Youping Wang, Yan Chen, Fei Zhao , miR-137 Suppresses the Phosphorylation of AKT and Improves the Dexamethasone Sensitivity in Multiple Myeloma Cells Via Targeting MITF, Current Cancer Drug Targets 2016; 16 (9) . https://dx.doi.org/10.2174/1568009616666160203114140
DOI https://dx.doi.org/10.2174/1568009616666160203114140 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Overview on Keratinocyte Growth Factor: From the Molecular Properties to Clinical Applications
Protein & Peptide Letters A New Era of Immunotherapy in Prostate Cancer
Current Molecular Pharmacology DNA Methylation Based Biomarkers in Non-Invasive Cancer Screening
Current Molecular Medicine Anticoagulants in Cirrhotic Patients: Controversies and Certainties in PVT Management
Cardiovascular & Hematological Agents in Medicinal Chemistry Human Umbilical Cord Blood as an Emerging Stem Cell Therapy for Diabetes Mellitus
Current Stem Cell Research & Therapy The Link Between Conventional and Novel Anti-Cancer Therapeutics with Thrombotic Microangiopathy
Drug Metabolism Letters Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry Statins-Mediated Inhibition of Rho GTPases as a Potential Tool in Anti-Tumor Therapy
Mini-Reviews in Medicinal Chemistry New Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia
Current Pharmaceutical Biotechnology Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?
Current Pharmacogenomics and Personalized Medicine Drug Resistance in Childhood Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology A Systematic Review of Selected Musculoskeletal Late Effects in Survivors of Childhood Cancer
Current Pediatric Reviews IT-143, A Polymer Micelle Nanoparticle, Widens Therapeutic Window of Daunorubicin
Pharmaceutical Nanotechnology Disulfiram, and Disulfiram Derivatives as Novel Potential Anticancer Drugs Targeting the Ubiquitin Proteasome System in Both Preclinical and Clinical Studies
Current Cancer Drug Targets Tumor-Derived Exosomes Contain microRNAs with Immunological Function: Implications for a Novel Immunosuppression Mechanism
MicroRNA JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?
Anti-Cancer Agents in Medicinal Chemistry K-Ras, Intestinal Homeostasis and Colon Cancer
Current Clinical Pharmacology Chronic Eosinophilic Leukemia, Not Otherwise Specified (CEL, NOS)
Current Cancer Therapy Reviews Current Metabolomic Methodologies & their Application to Thermal Stress
Current Metabolomics Survival and Immunosuppression Induced by Hepatocyte Growth Factor in Chronic Lymphocytic Leukemia
Current Molecular Medicine